121 results about "Clindamycin" patented technology

A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

The present invention provides a remedy for sarcoidosis, one of systemic granulomatous diseases, and a method for treating sarcoidosis. A remedy for sarcoidosis containing a Propionibacterium acnes-targeting antibiotic such as minocycline hydrochloride and clindamycin as an active component is prepared. Further, sarcoidosis is treated by administering this remedy for sarcoidosis to sarcoidosis patients.

A topical composition and methods of using same for treating various skin disorders or conditions. In a particular aspect, these compositions comprise a storage-stable benzoyl peroxide-containing composition in suspension and an antibiotic or pharmaceutically acceptable salt or ester thereof in solution and a retinoid or a pharmaceutically acceptable salt thereof in suspension, wherein the topical composition has a final pH of about 3 to about 8. In an alternative embodiment, these compositions comprise a storage-stable mixture of a retinoid or a pharmaceutically acceptable salt thereof and either a benzoyl peroxide-containing composition or clindamycin or a pharmaceutically acceptable salt thereof.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The invention discloses a medical composite alginate dressing containing antibacterial drugs and a preparation method thereof. In parts by weight, the medical composite alginate dressing comprises the following components: 50-99.9 parts of alginate and 0.05-10 parts of antibacterial drugs, The antibacterial drug is selected from gentamicin or its salt, neomycin or its salt, amikacin or its salt, fusidic acid or its salt, kanamycin or its salt, polycresol , mupirocin, sulfamethonium or its salt and clindamycin or its salt at least one. The medical composite alginate dressing of the present invention has strong ability to absorb exudate, has good water vapor transmission rate, can be biodegraded and has good biocompatibility, does not adhere to the wound and can quickly form gel after absorbing wound exudate , has strong moisturizing properties, can effectively promote wound healing, shorten wound repair time, can effectively prevent or treat sensitive bacterial infections, and can be widely used in acute and chronic wounds with exudate.

Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).

The invention provides a polypeptide having the molecular weight of 3321.6 Da and having an amino acid sequence as shown in SEQ ID NO.1. The invention also provides six derivatives of the polypeptide. The polypeptide and the derivatives thereof provided by the invention have efficient broad-spectrum bacteriostatic effect on gram positive bacteria and gram negative bacteria (especially having good killing effect on anti-clindamycin anaerobic propionibacterium acnes), fungi and yeasts, and have high activity (the concentration for killing the propionibacterium acnes in vitro can be only 0.125 mg/L). The polypeptide and the derivatives thereof can be applied in preparation of microbial bacterial and fungal infection-controlling and anti-inflammatory products, wherein the products include externally-applied disinfectants, anti-bacterial agents, wound-protection or infection-prevention dressings, acne treating drugs, skin care products, cosmetics and the like. The polypeptide is designed and synthesized based on a tryptophan bromide-containing fragment of a marine biological sea urchin, has stronger bacteria inhibiting or killing and anti-inflammatory effects and better stability, and can be used as an antibiotic substitute.

The invention provides an analysis method for detecting the clindamycin in cosmetic by use of high efficiency liquid chromatograph, and the invention is characterized in that octadecylsilane chemically bonded silica is adopted as the C18 column or the C8 column of filler, and an ultraviolet detector or a diode array detector are used to detect at the position of 190 to 380 nm; the mobile phase adopts ammonium dihydrogen phosphate solution-acetonitrile buffer solution or ammonium dihydrogen phosphate solution-methanol buffer solution; the sample is dissolved and extracted by dried methyl alcohol or acetonitrile, and, after extracted by ultrasound for 20 minutes, is centrifuged in 12000rpm/min for around 5 minutes. The clear liquid is the sample liquid, which is, if necessary, filtered by 0.45Mu meters filtering membrane for preparation; the qualitative analysis is conducted according to the sample retention time and the spectrogram, and the quantitative analysis is conducted according to the peak area. The invention has the advantages of high solution and sensitivity, and perfect reproducibility and selectivity as well as simple sample pre-treating method, thereby being applicable to microanalysis of clindamycin in cosmetic.

The invention discloses an integrated treatment process of clindamycin alkaline wastewater and belongs to the technical field of wastewater treatment. The process includes steps of: subjecting the clindamycin alkaline wastewater produced in a certain workshop section to Fe2<2+>/K2S2O8 oxidation pretreatment, and feeding the wastewater into a two-stage separation internal circulation anaerobic reactor and a multi-stage A/O reactor to perform biological treatment. The process integrates advantages of a Fe2<2+>/K2S2O8 oxidation technology, the two-stage separation internal circulation anaerobic reactor and the multi-stage A/O reactor. After treatment, the COD removal rate of the wastewater can be more than 99%, the ammonium-nitrogen removal rate can be more than 95%, and the total nitrogen removal rate can be more than 90%. In addition, a biogas product with economic value can be produced. The integrated process has characteristics of small agent adding amounts, high resistance to impact load, low system running costs, stable running, and the like.

A highly storage-stable composition for vaginal administration of clindamycin is disclosed which is useful for the treatment of bacterial vaginosis. The composition is a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat NF suppository base. Hard Fat NF suppository bases provide a clindamycin product having long term storage stability while providing efficacy against bacterial vaginosis which is equivalent to clindamycin vaginal creams.

The invention relates to the technical field of drugs for skin diseases, in particular to acne cream and a preparing method thereof. The acne cream is made from terbinafine hydrochloride, rifampicin, clindamycin, borneol, puerarin powder, poria cocos powder and dandelion. By means of compatibility of medicines contained in the acne cream, the acne cream can comprehensively treat pathomycete, bacteria and viruses which cause acne in the view of Western medicine and heat, poison and dampness which cause acne in the view of traditional Chinese medicine, treatment effect is thorough and remarkable, and patients who have acne can be cured comprehensively at low cost within a short period of time so as to return to normal life. Furthermore, the preparing method of the acne cream enables the treatment effect of the acne cream to be guaranteed, operation is easy, production cost is low, and the acne cream is convenient to carry and take.

The invention relates to the biotechnical field, in particular to primers and a method for rapidly identifying group B streptococcus and detecting drug resistance thereof and primer application. Four pairs of specific primers are as follows: a cfb gene primer pair cfb-F and cfb-R for identifying the group B streptococcus; an ermB gene primer pair ermB-F and ermB-R for detecting the drug resistance of the group B streptococcus to macrocyclic lactones; an mefA/ E gene primer pair mefA/E-F and mefA/E-R for detecting the drug resistance of the group B streptococcus to macrocyclic lactones; an linB gene primer pair linB-F and linB-R for detecting the drug resistance of the group B streptococcus to lincosamides. The method comprises the following steps: Step 1, DNA extraction; Step 2, primer design; Step 3, gene amplification; Step 4, result interpretation. According to the invention, the primers can identify GBS (group B streptococcus) in a genital tract of a pregnant woman and detect the drug resistanceof the GBS to erythromycin and clindamycin at the same time so as to guide clinical medication.

This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.

The present invention provides for a topical dermatological composition that includes diclofenac and clindamycin, in a pharmaceutically acceptable medium, wherein at least one of the diclofenac and clindamycin is at least partially microencapsulated.

The invention describes an antibiotic coating for porous bodies and its use. Into the porous system of non-metallic porous bodies and of metallic porous bodies, a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin myristate, the vancomycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin is introduced. The antibiotically coated, porous bodies are used as implants.